Product Description
Calcipotriene (calcipotriol) is a synthetic drug derived from calcitriol otherwise known as vitamin D. It works by regulating the production and growth of skin cells.
Mechanisms of Action: VDR Agonist,STAT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Psoriasis | Psoriasis | Psoriasis | Psoriasis
Known Adverse Events: Erythema | Folliculitis | Hypopigmentation | Urticaria | Psoriasis | Hypercalcemia | Headache
Company: LEO Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, New Zealand
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Psoriasis
Phase 1: Healthy Volunteers|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Healthy Volunteers|Oncology Unspecified |
2018-10-22 |
|
| CTR20130379 | P3 |
Active, not recruiting |
Psoriasis |
None |